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Renin-Angiotensin System Blockage for Reduction of Plasma 
Adiponectin Level in Maintenance Hemodialysis Patients
A Randomized Controlled Trial
Saeed Mardani,1 Maryam Heidari,1 Hamid Nasri2
Introduction. Plasma adiponectin level is markedly increased among 
patients on hemodialysis. This investigation aimed to evaluate the 
relationship between renin-angiotensin system blockade and serum 
adiponectin concentration in nondiabetic patients on hemodialysis.
Materials and Methods. This randomized double-blind controlled 
trial was conducted on a group of nondiabetic patients on regular 
hemodialysis. The first group received losartan, 12.5 mg twice per 
day for the 1st week, 25 mg twice per day during the 2nd week, and 
75 mg/d from the 3rd week to the end of the 16th week. Patients 
of the control group received placebo. Blood samples from all of 
the patients were collected at the beginning and at the end of the 
study to measure serum adiponectin.
Results. Seventy-three hemodialysis patients were divided randomly 
into the losartan group (40 patients) and the control group (33 
patients). The mean adiponectin level in all of the patients was 
10.6 ± 3.9 µg/mL. A significant decrease of serum adiponectin 
level was observed after 4 months of treatment with losartan 
(8.86 ± 3.43 µg/mL for losartan group versus 10.71 ± 3.94 µg/mL 
for the control group; P = .04). None of the patients had a serum 
potassium value greater than 5 mg/dL or hypotension during 
the intervention. There was no significant difference in serum 
potassium levels between the two groups. 
Conclusions. The decrease in serum adiponectin level in nondiabetic 
patients on regular hemodialysis by losartan might offer a potential 
protective approach in these patients. Mechanisms responsible for 
this reduction remain to be investigated.
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INTRODUCTION
Adiponectin is synthesized by white adipose 
tissue as a collagen-like protein.1 Adiponectin 
plays an important role in the regulation of body 
weight, lipid metabolism, insulin sensitivity, and 
inflammatory response.1,2 Also, adiponectin was 
demonstrated to have anti-inflammatory and anti-
atherogenic properties. Its anti-inflammatory effect 
is possibly conducted through the suppression 
and the attachment of monocytes to endothelial 
cells.1-3 Plasma adiponectin levels were shown 
to be inversely related to plasma insulin level, 
leptin and triglyceride levels, and also body mass 
index.2,3 It is also associated with vascular function 
independent of insulin sensitivity.2,3 
Recent findings have shown a protective 
function for adiponectin for the cardiovascular 
system, suggesting an inverse association with 
cardiovascular disease risks.1-8 Plasma adiponectin 
level is dependent on kidney function, being 
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markedly increased among patients with kidney 
impairment, and also in patients with end-stage 
renal disease and those on regular hemodialysis.3-9 
The underlying cause for the higher levels of 
circulating adiponectin in kidney disease patients is 
still unclear. It has been suggested that decreased 
renal clearance is the cause of increased plasma 
levels of adiponectin in patients with failing kidney 
function.1-8 While adiponectin might be a potential 
modulator of cardiovascular risk, epidemiological 
evidence has not consistently supported elevated 
levels being protective in hemodialysis patients.2-9 
Data on the association between adiponectin 
and outcomes in chronic kidney failure patients 
are scares. It has been shown that high serum 
adiponectin level predicts progression of end-
stage kidney disease and mortality in type 1 
diabetic patients.4,8,10-14 In kidney injury, some 
adipokines are involved through mediating 
endothelial dysfunction, triggering oxidative stress 
and inflammation, as well as stimulating renal 
sympathetic nervous activity, which diminishes 
cancellous bone but conversely increases cortical 
bone.4,8,10-14 Adipokines may also be involved 
in the development of renal anemia.2,4,8 Studies 
have shown that angiotensin II, as the main 
effector peptide of renin-angiotensin system,4,8,15 
is implicated in the development of renal, cardiac, 
and vascular pathologies.16 Recent studies have 
explored the relationship between angiotensin 
II, renin-angiotensin system, and adiponectin 
level.15-21 One study has shown the beneficial 
effects of losartan (angiotensin II type 1 receptor 
blocker) on plasma adiponectin level in patients 
with diabetic nephropathy.21 This investigation 
was designed to find out the relationship between 
renin-angiotensin system blockade and serum 
adiponectin concentration in a group of nondiabetic 
patients on regular hemodialysis.
MATERIALS AND METHODS
Study Population
This randomized double-blind controlled trial 
(registered by the Iranian Registry of Clinical Trials, 
2013112515535N1) was conducted on a group of 
nondiabetic patients on regular hemodialysis. The 
study was conducted at the hemodialysis section 
of Shahrekord University of Medical Sciences in 
2013 for a period of 4 months. All enrolled patients 
were on hemodialysis 3 times a week for 4 hours 
using low-flux dialysis filters with polysulfone 
membranes and reverse osmosis purified water 
and bicarbonate-base dialysis solution. Exclusion 
criteria were presence of diabetes mellitus, active 
or chronic infection, and taking angiotensin-
converting enzyme or renin-angiotensin blockers.22 
Also, patients receiving antibiotics, corticosteroids, 
pentoxifylline, or nutritional supplements, including 
various vitamins except for folic acid, within 3 
months prior to this trial, were excluded from 
the study.23
Measurement of Blood Pressure
Blood pressure was measured before each 
dialysis session and the results were recorded. 
It was measured on the right arm in a sitting 
position after at least 20 minutes rest with a 
mercury sphygmomanometer. Resting systolic 
blood pressures and 5th phase diastolic blood 
pressures were measured 3 times, while the 
participants were seated, and the 2nd and 3rd 
measurements were averaged.23-25 Hypertension 
was defined as systolic blood pressure of 130 mm 
Hg and higher or diastolic blood pressure of 85 
mm Hg and higher.23-25 
Study Protocol
The patients were assigned into 2 groups. The 
first group received losartan (purchased from 
Razak Co, Iran), 12.5 mg twice per day for the 1st 
week, 25 mg twice per day during the 2nd week, 
and 75 mg/d (50 mg in the morning and 25 mg for 
the evening) from the 3rd week to the end of the 
16th week. Patients of the control group received 
placebo in the same divisions. Blood samples from 
all patients were collected at the beginning and at 
the end of the study to measure plasma adiponectin. 
To avoid hypotension, other antihypertensive 
drugs were decreased or replaced with losartan 
(losartan group) during the treatment, especially 
when the dose of losartan increased as per the 
study protocol. During the 16 weeks of the study, 
serum potassium levels were checked every 2 weeks 
to avoid hyperkalemia. Blood pressure was also 
checked intensively before each dialysis session 
to avoid hypotension. After the end of 4 months, 
fasting serum samples were obtained to measure 
plasma adiponectin level. Body mass index was 
calculated as weight divided by squared height 
(kg/m2).
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Laboratory Analysis
Blood samples were taken after a long dialysis-
free weekend interval before the next hemodialysis, 
at 07:30 AM after a minimum 8-hour overnight 
fast to avoid the circadian and feeding impact on 
serum adiponectin fluctuations. Prior to the study 
and after intervention, serum adiponectin was 
measured in all of the patients by an enzyme-linked 
immunosorbent assay method, using the kits and 
protocol from Oegenium Laboratories (AviBion 
Human Adiponectin ELISA Kit, Helsinki, Finland). 
Blood urea nitrogen (BUN) and serum creatinine, 
potassium, sodium, calcium, and phosphorus were 
measured using standard kits and was done with 
standard automated techniques.
Ethics 
The research protocol followed the tenets of the 
Declaration of Helsinki and Good Clinical Practice 
guidelines. Informed consent was obtained the 
participants and the protocol was approved by 
the ethics committee of Shahrekord University of 
Medical Sciences. 
Statistical Analysis
Results were expressed as mean ± standard 
deviation and comparisons were considered 
significant when the P value was less than .05. 
The independent t test was used for comparison of 
continuous variables between the two groups. Data 
were analyzed using the SPSS software (Statistical 
Package for the Social Sciences, version 16.0, SPSS 
Inc, Chicago, Ill, USA).
RESULTS
Seventy-three nondiabetic hemodialysis patients 
(33 women and 44 men) were divided randomly 
into the losartan group (40 patients) and the control 
group (33 patients). The age range of the patients 
was from 13 to 91 years. Table 1 illustrates the 
patients’ characteristics before intervention. The 
mean adiponectin level in all of the patients was 
10.6 ± 3.9 µg/mL (range, 0.32 µg/mL to 17.41 
µg/mL). Table 2 shows the significant decrease 
of serum adiponectin level after 4 months of 
treatment with losartan (8.86 ± 3.43 µg/mL for 
losartan group versus 10.71 ± 3.94 µg/mL for the 
control group; P = .04), as compared with those 
in the control group. None of the patients had 
a serum potassium value greater than 5 mg/dL. 
None of the patients had hypotension during the 
intervention. There was no significant difference in 
serum potassium levels between the two groups. 
The Figure shows serum potassium fluctuations 
in the two groups. Table 3 shows the hemoglobin 
levels and KT/V values before and after treatment 
with losartan. There was no significant difference 
in KT/V before and after the treatment (P = .29).
Characteristic Losartan Group (n = 40)
Control Group
(n = 33) P
Age, y 59.65 ± 19.02 53.94 ± 20.90 .93
Male sex, % 55 54 .97
Body weight, kg 59.86 ± 13.40 56.58 ± 15.39 .33
Body mass index, kg/m2 3.85 ± 22.42 3.99 ± 21.31 .22
Systolic blood pressure, mm Hg 123.5 ± 21.90 125.45 ± 22.37 .71
Diastolic blood pressure, mm Hg 69.50 ± 9.59 71.21 ± 10.20 .46
Serum sodium, mg/dL 140.15 ± 2.87 141.88 ± 2.30 .007
Serum potassium, mg/dL 4.84 ± 0.56 5.16 ± 0.79 .06
Serum calcium, mg/dL 8.92 ± 0.55 9.09 ± 0.54 .20
Serum phosphorus, mg/dL 5.31 ± 1.16 4.88 ± 1.07 .10
Table 1. Clinical and Demographic Characteristics of Nondiabetic Hemodialysis Patients Before Intervention*
*Values are mean ± standard deviation, except for sex distribution, which is percentage.
Adiponectin Losartan Group (n = 40)
Control Group
(n = 33) P
Before treatment, µg/mL 10.52 ± 3.72 (0.3 to 17.4) 10.60 ± 4.12 (1.0 to 16.9) .93
After treatment, µg/mL 8.86 ± 3.43 (0.5 to 15.0) 10.71 ± 3.94 (1.0 to 16.9) .04
Table 2. Adiponectin Level Before and After Treatment With Losartan*
*Values are mean ± standard deviation (range).
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DISCUSSION
This study documented a decline in serum 
adiponectin level after 4 months of losartan 
therapy. To evaluate the effects of adiponectin 
on appearance of protein-energy wasting, Kaynar 
and colleagues examined 150 patients with chronic 
kidney disease.26 They found an elevated level 
of adiponectin in hemodialysis, predialysis, and 
peritoneal dialysis patients in comparison to 
their control group. They showed a significant 
positive correlation between presence of protein-
energy wasting and serum adiponectin level. They 
concluded that high serum adiponectin level might 
have a role in the development of protein-energy 
wasting among dialysis patients.26 Recently, Okuno 
and colleagues conducted a study to assess the 
possible role of adiponectin in mineral and bone 
disorders of dialysis patients. The study conducted 
on 114 Japanese male hemodialysis patients.27 They 
found a significant positive correlation between 
plasma adiponectin and serum N-telopeptide of 
type I collagen. They concluded that increased 
levels of serum adiponectin were associated 
with a decrease in bone mineral density in male 
hemodialysis patients.27
Furthermore, adiponectin may play a role in bone 
and mineral disorder, possibly in bone resorption of 
patients on dialysis.27-31 Likewise, in a study on 44 
hemodialysis patients, Lee and colleagues found that 
plasma adiponectin level was significantly higher 
in malnourished patients than in well-nourished 
patients.31 They concluded that plasma adiponectin 
level reflected the nutritional-inflammation status 
of hemodialysis patients and also adiponectin 
might also be accompanied with dyslipidemia, 
insulin resistance, and the inflammatory response 
in these patients.31 To examine the association 
between plasma adiponectin and mortality in the 
earlier stages of chronic kidney disease, Menon 
and associates conducted a study with a 10-year 
follow-up and found that high, rather than low, 
plasma adiponectin concentration was associated 
with increased mortality in patients with chronic 
kidney disease stages 3 to 4.32 Recent studies 
suggest that in patients with nondiabetic chronic 
kidney disease, elevated adiponectin may be a novel 
predictor for chronic kidney disease progression 
in men.1-6,20,33-34 Furthermore, it has been proposed 
that adiponectin enhances energy expenditure, 
and high plasma adiponectin levels might not be 
a valuable marker in chronic kidney disease.35
Hence, it seems that any attempts to decrease 
the adiponectin level may influence the survival 
of hemodialysis patients. In a study on 80 patients 
with type 2 diabetic nephropathy who were 
randomly divided into 2 groups for losartan and 
amlodipine, Gou and colleagues found declines in 
fasting insulin and adiponectin levels by losartan 
therapy.21 They concluded that this effect of 
losartan might offer potential protection in diabetic 
nephropathy. Similar results were also obtained 
in our investigation. However, few studies have 
published regarding the capacity of angiotensin 
receptor blockers to increase or decrease the plasma 
adiponectin concentration. To the best of our 
knowledge, this is the first double-blind clinical 
trial on the effect of losartan on adiponectin level in 
hemodialysis patients. We assumed that decreased 
plasma adiponectin by losartan was a beneficial 
effect in hemodialysis patients. It has been found 
that increased adiponectin levels are strongly 
associated with all-cause and cardiovascular 
mortality in patients with chronic kidney failure 
Parameter Before Treatment After Treatment
Hemoglobin, g/dL 10.51 ± 1.96 (6.6 to 15.3) 9.35 ± 1.69 (5.7 to 14.1)
KT/V 1.43 ± 0.32 (0.5 to 2.7) 1.48 ± 0.22 (0.7 to 1.9)
Table 3. Hemoglobin Levels and KT/V Values of All Participants Before and After Treatment With Losartan*
*Values are mean ± standard deviation (range).
Serum potassium fluctuations during the study.
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or hemodialysis patients.36-46 However, further 
studies are required to confirm this finding and 
to reveal the underlying mechanisms.
CONCLUSIONS
Our results demonstrate for the first time that 
adiponectin level in nondiabetic patients on regular 
hemodialysis is decreased by the angiotensin 
receptor blockers, which might offer a protective 
role in hemodialysis patients. The mechanisms 
responsible for this decrement during short-course 
treatment with losartan remain to be investigated.
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